

Sister Study Cervical Cancer Outcomes (Any Behavior)¹ and Characteristics: Data Release 11.1²

| | N | % of cohort |
|--|------------|-------------------|
| Total Cases³ | 605 | 1.2 |
| Timing, Behavior, and Site | N | % of cases |
| Baseline | 556 | 91.9 |
| Invasive | 496 | 82.0 |
| Endocervix | 5 | 0.8 |
| Unknown ⁴ | 491 | 81.2 |
| <i>In situ</i> | 60 | 9.9 |
| Endocervix | 2 | 0.3 |
| Unknown ⁴ | 58 | 9.6 |
| Unknown timing – Invasive – Unknown ⁵ | 2 | 0.3 |
| Incident | 47 | 7.8 |
| Invasive | 29 | 4.8 |
| Endocervix | 6 | 1.0 |
| Exocervix | 1 | 0.2 |
| Unknown ⁴ | 22 | 3.6 |
| <i>In situ</i> | 18 | 3.0 |
| Endocervix | 7 | 1.2 |
| Unknown ⁴ | 11 | 1.8 |
| Incident | 46 | |
| Race/Ethnicity⁶ | | |
| Non-Hispanic White | 36 | 76.6 |
| Non-Hispanic Black | 9 | 19.1 |
| Hispanic | 1 | 2.1 |
| Other | 1 | 2.1 |
| Age (in years) at Diagnosis | | |
| Under 50 | 9 | 19.1 |
| 50-64 | 25 | 53.2 |
| 65 and older | 13 | 27.7 |
| Diagnosis Confirmation⁷ | | |
| Medical | 30 | 63.8 |
| NDI Plus or death certificate only | 1 | 2.1 |
| None | 16 | 34.0 |
| Incident – Medically Confirmed | 30 | |
| Stage at Diagnosis⁸ | | |
| I | 7 | 53.8 |
| II | 2 | 15.4 |
| III | 2 | 15.4 |
| IV | 2 | 15.4 |
| Missing, cannot stage ⁹ | 17 | |

- ¹ Cancer events are defined by the following ICD10 cancer codes: invasive cervix (C53) and *in situ* cervix (D06). Other ICD10 cancer codes that may be used when cervix is indicated as one of the favored primary sites: invasive female genital organ (C57.9), invasive unspecified site (C80), *in situ* female genital organ (D07.30), uncertain behavior of female genital organ (D39.8, D39.9), unspecified behavior of genitourinary organ (D49.59).
- ² Data release 11.1 includes outcomes from follow-up phases that closed on or before 9/30/2021, excluding all data from participants who have withdrawn their data from the study [n=5].
- ³ Excludes cancer diagnoses where cervical site of origin could not be ruled out, but it is not the favored site [n=6].
- ⁴ Unknown site generally includes cervix - not specified, with the following exception: baseline and incident include invasive diagnoses where cervix is one of the favored primary site(s) but other reproductive site(s) cannot be ruled out [baseline: n=3; incident: n=1].
- ⁵ Unknown timing represents cases that are unknown if diagnosis at or prior to baseline vs. post-baseline (i.e. incident case).
- ⁶ Race/ethnicity: precedence given to Hispanic ethnicity first, then Black race, then other race, then White race.
- ⁷ Medical confirmation of reported cervical cancer is generally from pathology report but may include other medical documentation; National Death Index (NDI) Plus or death certificate confirmation is specific to cases that do not have medical confirmation.
- ⁸ TNM stage at diagnosis is only available for cases with medical confirmation and is classified according to the American Joint Committee on Cancer (AJCC) 8th Edition Staging System.
- ⁹ Includes *in situ* cervical cancer cases that are no longer staged by the International Federation of Gynecology and Obstetrics (FIGO) and the American Joint Committee on Cancer (AJCC) 8th edition staging manual [n=16].